Search Results

You are looking at 11 - 20 of 45 items for :

  • "hepatitis C virus" x
  • Refine by Access: All x
Clear All
Full access

2 baseline/change with tivozanib and use modeling to correlate exposure with biomarker change and the primary outcome measure of PFS Determine the change in viral load (hepatitis B virus [HBV] and hepatitis C virus [HCV]) during therapy in patients

Full access

Shiva Kumar R. Mukkamalla, Hussain M. Naseri, Byung M. Kim, Steven C. Katz, and Vincent A. Armenio

and the increased incidence of hepatitis C virus infection. 4 The etiology and pathogenesis of CCA remain poorly understood. Although most CCAs can arise de novo, risk factors include primary sclerosing cholangitis (PSC), alcohol consumption, liver

Full access

AFP response; toxicity; and tolerability in subsets defined by hepatitis B virus (HBV), hepatitis C virus, Asian, and non-Asian status Compare degree of association between median TTP and OS with response by RECIST version 1.1 and modified RECIST

Full access

receptor 2 baseline/change with tivozanib, and use modeling to correlate exposure with biomarker change and the primary outcome measure of PFS Determine the change in viral load (hepatitis B virus [HBV] and hepatitis C virus [HCV]) during therapy in

Full access

Radhika Gangaraju, Soo J. Kim, Jing-Fei Dong, Sabina Swierczek, and Josef T. Prchal

treated with pegylated interferon-a/2b . Scand J Gastroenterol 2007 ; 42 : 408 – 409 . 14. Yagita M Uemura M Nakamura T . Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic

Full access

Omid S. Shaye and Alexandra M. Levine

unmutated cases with frequent 7q deletion and adverse clinical course . Blood 2002 ; 99 : 1299 – 1304 . 59. Mele A Pulsoni A Bianco E . Hepatitis C virus and B cell non-Hodgkin lymphomas: an Italian multicenter case-control study . Blood

Full access

Ghassan K. Abou-Alfa

nonresectable disease . Expert Rev Anticancer Ther 2008 ; 8 : 1743 – 1749 . 31 Giambartolomei S Covone F Levrero M . Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV

Full access

Hamdy A. Azim, Abdul-Rahman Jazieh, and Mohammad Jahanzeb

cancers and usually secondary to hepatitis C virus (HCV). 8 In a subgroup analysis of a pivotal sorafenib study, a greater benefit of this drug was seen among patients with HCV-associated HCC. Another example is bladder cancer, which is usually of

Full access

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner

. 1 Moreover, Tanaka et al 2 reported that the incidence of HCC is expected to increase over the next 2 decades. 2 Cirrhosis is the most common risk factor, which is also a consequence of hepatitis C virus (HCV) or hepatitis B virus (HBV) infections

Full access

Chloe E. Atreya, Eric A. Collisson, Meyeon Park, James P. Grenert, Spencer C. Behr, Amalia Gonzalez, Jonathan Chou, Samantha Maisel, Terence W. Friedlander, Chris E. Freise, Jun Shoji, Thomas J. Semrad, Jessica Van Ziffle, and Peter Chin-Hong

Background Reporting on transmission of HIV and hepatitis C virus from an organ donor to transplant recipients 1 spurred the uptake of routine nucleic acid testing on organ donor sera, 2 leading to a significant decline in viral transmission